BACKGROUND: The authors reported their experience with radical cystectomy for transitional cell carcinoma (TCC) of the bladder. They compared pathologic features and survival rates between older and younger patients. METHODS: The authors retrospectively reviewed the records of 1054 patients who underwent radical cystectomy for bladder TCC between 1971 and 1997. Four age groups were compared: < 60 years old at the time of cystectomy (n = 310), 60-69 years old (n = 381), 70-79 years old (n = 313), and >/= 80 years old (n = 50). RESULTS: There were no significant differences in pathologic features among the groups regarding frequency of carcinoma in situ, high-grade disease, p53 status, and lymph node positivity. However, in the age groups < 60, 60-69, 70-79, and >/= 80, 45%, 49%, 51%, and 72% of patients, respectively, had extravesical TCC (P=0.004). Significant differences also were seen in the proportion of patients who received adjuvant chemotherapy (26%, 26%, 15%, and 6%, respectively; P < 0.001). The 5-year overall survival rates for patients < 60, 60-69, 70-79, and >/= 80 years old were 72%, 58%, 54%, and 33%, respectively (P < 0.001). The 5-year disease recurrence-free survival rates were 75%, 65%, 68%, and 45%, respectively (P = 0.003). The elderly had a lower probability of receiving adjuvant chemotherapy. CONCLUSIONS: Elderly patients undergoing cystectomy for TCC had similar pathologic features (except for disease stage) as younger patients. In the current series, elderly patients undergoing cystectomy had a higher pathologic stage and were less likely to receive adjuvant chemotherapy. The elderly had worse disease recurrence-free survival rates. Further work is needed to identify the causes for this and to develop strategies to improve cancer control in elderly patients. (c) 2004 American Cancer Society
BACKGROUND: The authors reported their experience with radical cystectomy for transitional cell carcinoma (TCC) of the bladder. They compared pathologic features and survival rates between older and younger patients. METHODS: The authors retrospectively reviewed the records of 1054 patients who underwent radical cystectomy for bladder TCC between 1971 and 1997. Four age groups were compared: < 60 years old at the time of cystectomy (n = 310), 60-69 years old (n = 381), 70-79 years old (n = 313), and >/= 80 years old (n = 50). RESULTS: There were no significant differences in pathologic features among the groups regarding frequency of carcinoma in situ, high-grade disease, p53 status, and lymph node positivity. However, in the age groups < 60, 60-69, 70-79, and >/= 80, 45%, 49%, 51%, and 72% of patients, respectively, had extravesical TCC (P=0.004). Significant differences also were seen in the proportion of patients who received adjuvant chemotherapy (26%, 26%, 15%, and 6%, respectively; P < 0.001). The 5-year overall survival rates for patients < 60, 60-69, 70-79, and >/= 80 years old were 72%, 58%, 54%, and 33%, respectively (P < 0.001). The 5-year disease recurrence-free survival rates were 75%, 65%, 68%, and 45%, respectively (P = 0.003). The elderly had a lower probability of receiving adjuvant chemotherapy. CONCLUSIONS: Elderly patients undergoing cystectomy for TCC had similar pathologic features (except for disease stage) as younger patients. In the current series, elderly patients undergoing cystectomy had a higher pathologic stage and were less likely to receive adjuvant chemotherapy. The elderly had worse disease recurrence-free survival rates. Further work is needed to identify the causes for this and to develop strategies to improve cancer control in elderly patients. (c) 2004 American Cancer Society
Authors: M May; H-M Fritsche; C Gilfrich; S Brookman-May; M Burger; W Otto; C Bolenz; L Trojan; E Herrmann; M S Michel; C Wülfing; A Tiemann; S C Müller; J Ellinger; A Buchner; C G Stief; D Tilki; W F Wieland; T Höfner; M Hohenfellner; A Haferkamp; J Roigas; O Müller; P Bretschneider-Ehrenberg; M Zacharias; S Gunia; P J Bastian Journal: Urologe A Date: 2011-07 Impact factor: 0.639
Authors: M W Kramer; A Heinisch; G Wegener; M Abbas; C von Klot; I Peters; H Tezval; T R Herrmann; M A Kuczyk; A S Merseburger Journal: Urologe A Date: 2014-02 Impact factor: 0.639
Authors: Jim Zhong; Jeffrey Switchenko; Naresh K Jegadeesh; Richard J Cassidy; Theresa W Gillespie; Viraj Master; Peter Nieh; Mehrdad Alemozaffar; Omer Kucuk; Bradley Carthon; Christopher P Filson; Mehmet A Bilen; Ashesh B Jani Journal: Am J Clin Oncol Date: 2019-01 Impact factor: 2.339
Authors: John L Gore; Mark S Litwin; Julie Lai; Elizabeth M Yano; Rodger Madison; Claude Setodji; John L Adams; Christopher S Saigal Journal: J Natl Cancer Inst Date: 2010-04-16 Impact factor: 13.506
Authors: Ifeanyichukwu I Megwalu; Anna Vlahiotis; Mohamed Radwan; Jay F Piccirillo; Adam S Kibel Journal: Eur Urol Date: 2007-11-05 Impact factor: 20.096
Authors: Nicholas J Farber; Izak Faiena; Viktor Dombrovskiy; Alexandra L Tabakin; Brian Shinder; Rutveej Patel; Sammy E Elsamra; Thomas L Jang; Eric A Singer; Robert E Weiss Journal: Bladder Cancer Date: 2018-01-20